Biotechnology company GeoVax Labs will present at the Emerging Growth Conference on April 16, 2025, with CEO David Dodd addressing the recent termination of its contract with the Biomedical Advanced Research and Development Authority (BARDA).
The conference presentation, scheduled for 3:40 pm ET, will provide shareholders and investors an opportunity to gain direct insights into the company's current strategic positioning. Dodd will focus on the implications of the BARDA contract termination for the company's lead clinical program, GEO-CM04S1, a next-generation COVID-19 vaccine.
GeoVax's COVID-19 vaccine is currently being evaluated in three Phase 2 clinical trials, targeting specific patient populations including immunocompromised patients, those with chronic lymphocytic leukemia, and as a booster for individuals previously vaccinated with mRNA vaccines.
The conference will be a live, interactive online event, allowing participants to submit questions in advance or during the presentation. An archived webcast will also be available for those unable to attend the live event.
Beyond its COVID-19 vaccine program, GeoVax continues to advance its oncology research, including a gene-directed therapy for solid tumors and an ongoing clinical trial for advanced head and neck cancers. The company is also developing a vaccine targeting Mpox and smallpox, demonstrating its commitment to addressing diverse infectious disease challenges.
